healthevidencedigest

Tag: pediatrics

  • Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

    Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

    The essentials: On June 8, 2026, the FDA approved an expanded indication for Hympavzi (marstacimab-hncq, Pfizer) to include two additional patient populations: patients aged 12 years and older with hemophilia A or B who have inhibitors, and pediatric patients aged 6 to 11 years with hemophilia A or B with or without inhibitors. Hympavzi was originally approved in October 2024 for patients aged 12 years and older without inhibitors. The complete current indication: routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 6 years and older with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency), with or without inhibitors. First-in-class designations from the expanded approval: Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. Mechanism: Hympavzi targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulant that brakes the initiation of coagulation. By inhibiting TFPI, marstacimab restores the coagulation pathway in a way that works regardless of whether the patient is deficient in factor VIII or factor IX, and regardless of whether inhibitory antibodies are present against those factors. This is why it works in both hemophilia A and B, and in patients with inhibitors. The clinical basis: Phase 3 BASIS trial (NCT03938792) inhibitor cohort and Phase 3 BASIS KIDS trial (NCT05611801). BASIS inhibitor cohort: 93% reduction in mean treated annualized bleeding rate (ABR) versus on-demand bypassing agent therapy (1.4 [95% CI 0.9 to 2.3] versus 19.8 [95% CI 16.1 to 24.3]; ratio 0.07 [95% CI 0.04 to 0.12]; p less than 0.0001). BASIS KIDS (ages 6 to 17): mean ABR 1.8 versus historical model-based mean ABR 3.6 with prior routine prophylaxis. Pediatric inhibitor subgroup (ages 6 to under 18; n=14): mean ABR 1.4 (99% CI 0.5 to 4.5) versus historical mean ABR 18.9 (99% CI 14.2 to 25.2). Ages 6 to 11 cohort (n=7): mean ABR 1.3 (99% CI 0.5 to 3.4). Warnings: thromboembolic events occurred in 2 of 259 patients in the open-label extension study; hypersensitivity reactions; embryo-fetal toxicity; increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2. Dosing: once weekly subcutaneous injection; available as 75 mg/0.5 mL and 150 mg/mL prefilled syringe or autoinjector pen. No routine treatment-related laboratory monitoring required.

    Hemophilia is, at its core, a disease of imbalance. The coagulation cascade that allows blood to clot and stop bleeding is a tightly regulated system of amplification, and in hemophilia A or B, a critical amplifier is missing or deficient. The consequences, when left untreated or inadequately treated, are relentless: joint bleeds that destroy cartilage and deform limbs, muscle hemorrhages that compress nerves and blood vessels, and intracranial bleeding that can be fatal. For patients with a specific complication called inhibitors, even the standard replacement therapy stops working, leaving them in a position where a category of medications designed to save their lives has become ineffective against their own immune response.

    Hympavzi (marstacimab-hncq), originally approved in October 2024, takes an entirely different approach to hemophilia prophylaxis. Rather than replacing the deficient clotting factor, it blocks a natural brake on the coagulation system: tissue factor pathway inhibitor (TFPI). On June 8, 2026, the FDA expanded Hympavzi’s approved indication to two of the groups most in need of this approach: patients with hemophilia A or B who have inhibitors (where factor replacement therapy either cannot work or works inadequately), and children aged 6 to 11 years, the youngest pediatric age group that can benefit from a once-weekly subcutaneous prophylactic therapy.

    This post covers what hemophilia is, why inhibitors represent such a significant clinical challenge, how the TFPI mechanism works and why it is effective across both hemophilia types and inhibitor-positive patients, what the BASIS and BASIS KIDS trial data shows, and what the expanded approval means for families and clinicians managing these patients.

    What Hemophilia Is: A Brief Overview

    Hemophilia is a rare, X-linked recessive bleeding disorder caused by deficiency or dysfunction of specific coagulation factors. Two major types are recognized:

    Hemophilia A is caused by deficiency or dysfunction of factor VIII (FVIII). It is the more common type, affecting approximately 1 in 5,000 male births.

    Hemophilia B is caused by deficiency or dysfunction of factor IX (FIX). It affects approximately 1 in 25,000 male births.

    Both conditions result in a dysfunctional coagulation cascade, the sequential activation of clotting proteins that ultimately converts fibrinogen to fibrin and forms a stable blood clot. Without adequate FVIII or FIX activity, the intrinsic pathway of coagulation cannot amplify adequately, resulting in delayed, insufficient clot formation. Minor injuries that healthy individuals handle without consequence become prolonged bleeding events in hemophilia. Spontaneous joint and muscle bleeds, which occur without obvious trauma, are a hallmark of severe hemophilia and are responsible for the progressive arthropathy (joint destruction) that historically defined the long-term morbidity of the disease.

    The standard of care for moderate to severe hemophilia has been prophylactic factor replacement: infusing FVIII or FIX concentrate on a scheduled basis, typically two to three times per week for IV formulations or less frequently for extended half-life products, to maintain factor levels high enough to prevent spontaneous bleeding. This approach has dramatically improved outcomes over the past four decades. It requires, however, venous access and intravenous administration, which is particularly challenging in young children whose veins are small and who may require port placement.

    The inhibitor problem

    Inhibitors are neutralizing antibodies against the infused clotting factor, most commonly FVIII in hemophilia A. They develop in approximately 30% of patients with severe hemophilia A and in a smaller proportion of hemophilia B patients, typically early in treatment. When inhibitors are present, the infused factor is rapidly neutralized before it can participate in clotting, and standard prophylaxis becomes ineffective.

    Managing hemophilia with inhibitors has historically required bypassing agents, products that activate the coagulation cascade at steps downstream of where FVIII and FIX normally act: recombinant factor VIIa (NovoSeven) and activated prothrombin complex concentrate (aPCC, FEIBA). These agents work differently from standard factor replacement and are less precisely dosed, making achieving predictable bleeding protection more challenging. Their use is also expensive, requires intravenous administration, and when used on-demand (only when bleeding occurs) rather than prophylactically, leaves patients with significant residual bleeding burden.

    Why non-factor therapies are a breakthrough for inhibitor patients The development of non-factor hemostatic therapies, which restore hemostasis by mechanisms that bypass the deficient factor entirely, represents one of the most significant advances in hemophilia management in decades. Emicizumab (Hemlibra), approved in 2017 for hemophilia A with inhibitors, was the first such therapy and demonstrated dramatic reductions in bleeding rates in a population that had previously had very limited prophylactic options. It works by bridging FIXa and FX, mimicking the co-factor function of FVIII specifically. However, because emicizumab bridges FIXa (factor IX in activated form), it works only in hemophilia A: it provides no benefit in hemophilia B because FIX is not a bridging partner for its mechanism. Marstacimab’s TFPI inhibition mechanism is active in both hemophilia A and hemophilia B regardless of inhibitor status, because it restores hemostasis upstream of where either FVIII or FIX deficiency disrupts the cascade. This is why Hympavzi’s expanded indication covers both hemophilia types and both inhibitor-positive and inhibitor-negative patients.

    The Science: How Marstacimab Works

    Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant protein. It functions as a feedback inhibitor of the extrinsic pathway of coagulation: after tissue factor and factor VIIa initiate clotting in response to vascular injury, TFPI rapidly inhibits the TF-FVIIa-FXa complex, effectively braking the initial clotting signal after it has had time to initiate.

    In healthy individuals, this brake is appropriate. The extrinsic pathway generates only a small initial burst of thrombin, and the intrinsic pathway (which requires FVIII and FIX) amplifies this initial signal to generate the large amounts of thrombin needed for stable clot formation. When FVIII or FIX is deficient, the initial thrombin burst generated by the extrinsic pathway is inadequate, and the amplification step through the intrinsic pathway cannot compensate. TFPI’s braking of the extrinsic pathway further limits the already insufficient hemostatic response.

    Marstacimab is a human monoclonal antibody that targets the Kunitz 2 (K2) domain of TFPI with high specificity. The K2 domain is the site through which TFPI inhibits FXa, a critical downstream clotting protein. By blocking the K2 domain, marstacimab prevents TFPI from inhibiting FXa as efficiently. This allows the coagulation cascade to generate more thrombin from the extrinsic pathway initiation step, partially compensating for the deficient intrinsic amplification. The result is a shift in the coagulation balance toward clot formation even in the absence of adequate FVIII or FIX.

    Critically, this mechanism functions regardless of:

    • Whether the patient is deficient in FVIII (hemophilia A) or FIX (hemophilia B)
    • Whether inhibitory antibodies are present against FVIII or FIX
    • The severity of the underlying factor deficiency

    Because marstacimab acts on a checkpoint in the coagulation cascade that is common to both hemophilia types and is entirely upstream of where inhibitors act against replacement factors, it provides hemostatic coverage across the full breadth of the expanded indication.

    The Original Approval and What the Expansion Adds

    Original approval (October 2024)

    Hympavzi was initially approved in October 2024 for routine prophylaxis in patients aged 12 years and older with hemophilia A without FVIII inhibitors or hemophilia B without FIX inhibitors, based on the Phase 3 BASIS trial in the non-inhibitor cohort.

    The June 2026 expansion

    The June 8, 2026 expansion adds two critically important populations:

    Population 1: Patients aged 12 years and older with hemophilia A or B who have inhibitors. This is the group with the most limited treatment options prior to this approval, for whom on-demand bypassing agents were often the only recourse for bleeding management.

    Population 2: Pediatric patients aged 6 to 11 years with hemophilia A or B, with or without inhibitors. This extends Hympavzi’s reach to younger children, a population in whom venous access for IV therapy is a significant practical challenge, and for whom a once-weekly subcutaneous injection is potentially far more manageable than frequent IV infusions.

    Together, the expanded and original indications give Hympavzi a single consolidated label: routine prophylaxis for adults and pediatric patients aged 6 years and older with hemophilia A or B, with or without inhibitors.

    The Clinical Evidence: BASIS Inhibitor Cohort and BASIS KIDS

    BASIS trial (NCT03938792): the inhibitor cohort data

    BASIS (NCT03938792) was a Phase 3, global, open-label trial evaluating marstacimab in patients with hemophilia A or B with and without inhibitors. The trial included an inhibitor cohort of patients who had previously received on-demand (OD) bypassing agent therapy for bleeding episodes. This population represents the clinical severity of inhibitor disease: patients who had not been on prophylaxis and were relying on reactive treatment when bleeds occurred.

    The primary efficacy comparison in the inhibitor cohort was marstacimab prophylaxis versus on-demand bypassing agent therapy. The results were striking:

    OutcomeMarstacimab prophylaxisOn-demand bypassing agent (historical)Comparison
    Mean treated annualized bleeding rate (ABR)1.4 (95% CI 0.9 to 2.3)19.8 (95% CI 16.1 to 24.3)93% reduction; ratio 0.07 (95% CI 0.04 to 0.12); p less than 0.0001

    Source: Clinical Advisor. Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. June 2026. Hematology Advisor. June 2026. Pfizer press release, June 8, 2026.

    A 93% reduction in mean treated annualized bleeding rate compared to on-demand bypassing therapy is a clinically substantial finding. Patients going from a mean treated ABR of approximately 19.8 bleeds per year to 1.4 bleeds per year is a transformation in disease burden. The most devastating consequence of hemophilia with inhibitors has always been the inability to prevent spontaneous joint bleeds because on-demand therapy, by definition, does not begin until bleeding has already started. Each prevented bleed under prophylaxis is a joint or muscle or organ that did not bleed.

    This comparison is against on-demand therapy because patients in the inhibitor cohort had not previously been on prophylaxis. An interpretive note: comparing against on-demand is a favorable comparison for the active treatment; a head-to-head comparison against existing prophylactic bypassing agent regimens would be more demanding. Nonetheless, the magnitude of the reduction is substantial and clinically meaningful.

    BASIS KIDS trial (NCT05611801): the pediatric data

    BASIS KIDS (NCT05611801) was a Phase 3, global, open-label trial evaluating the safety and efficacy of marstacimab in children aged 1 to 17 years with hemophilia A or B, with or without inhibitors. Interim results from this trial supported the FDA’s expanded approval for the 6-to-11-year age group.

    PopulationMean ABR with marstacimabComparison (historical model-based)
    Ages 6 to 17, all patients (overall BASIS KIDS)1.83.6 (prior routine prophylaxis)
    Ages 6 to under 18 with inhibitors (n=14)1.4 (99% CI 0.5 to 4.5)18.9 (99% CI 14.2 to 25.2)
    Ages 6 to 11 cohort (n=7)1.3 (99% CI 0.5 to 3.4)—

    Source: Clinical Advisor. CheckRare. BASIS KIDS NCT05611801.

    The pediatric inhibitor subgroup data is particularly notable: children with hemophilia and inhibitors achieved a mean ABR of 1.4 with marstacimab prophylaxis compared to a historical model-based mean of 18.9 with on-demand bypassing therapy. For the youngest cohort (ages 6 to 11), the mean ABR of 1.3 indicates that the same degree of bleeding rate reduction is achievable in younger children.

    The comparison in BASIS KIDS against historical model-based rates (rather than a randomized parallel arm) is appropriate for a pediatric rare disease trial, where randomizing young children to a control arm receiving inferior therapy would be ethically difficult and practically challenging. The historical modeling approach uses well-characterized natural history data from the hemophilia population to provide a reference benchmark.

    What Makes This Approval Particularly Significant

    The hemophilia B inhibitor gap

    The most significant first-in-class designation from this expansion is that Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. This deserves specific explanation.

    Emicizumab (Hemlibra), the landmark non-factor therapy approved for hemophilia A with inhibitors in 2017, works by bridging activated factor IXa and factor X, mimicking the cofactor function of FVIII. This mechanism is specific to hemophilia A: it does not provide any benefit in hemophilia B because factor IXa is not the relevant enzyme that needs a cofactor. Patients with hemophilia B and inhibitors have therefore had no approved subcutaneous prophylactic non-factor therapy option. For them, marstacimab’s TFPI inhibition mechanism, which is indifferent to whether the underlying deficiency is in FVIII or FIX, represents the first approval in this category.

    Once-weekly subcutaneous administration without routine laboratory monitoring

    Hympavzi is administered once weekly by subcutaneous injection. The therapy does not require routine treatment-related laboratory monitoring, which distinguishes it from many hemophilia treatments that require regular factor level measurement or trough level testing to guide dosing. For families managing pediatric hemophilia, reducing the blood draw burden alongside simplifying the injection schedule to once weekly is a meaningful quality-of-life improvement.

    Patients aged 12 years and older may self-inject after proper training. For children aged 6 to 11, caregiver administration is expected.

    Safety: What the Prescribing Information Covers

    The prescribing information for Hympavzi includes several important warnings:

    Thromboembolic events: Two thromboembolic events occurred among 259 patients in the open-label extension study. Because marstacimab shifts the coagulation balance toward clot formation by removing the TFPI brake on the extrinsic pathway, the theoretical risk of thrombosis is inherent to its mechanism of action. Monitor patients for signs and symptoms of thromboembolic events. The absolute rate was low (2 of 259 patients in the extension), but the mechanism-based concern means clinical vigilance is appropriate.

    Laboratory changes: Increases in fibrin D-dimer and prothrombin fragment 1.2 have been observed with marstacimab. These are laboratory markers of coagulation activation and fibrin turnover. They are consistent with the drug’s mechanism (enhanced coagulation pathway activity) but require awareness in clinical monitoring. Do not interpret elevated D-dimer as diagnostic for thrombosis without clinical correlation in patients receiving marstacimab.

    Hypersensitivity reactions: As with all monoclonal antibodies, hypersensitivity reactions including anaphylaxis may occur. Patients should be informed of the symptoms and instructed to seek immediate medical attention if they occur.

    Embryo-fetal toxicity: Based on the mechanism of action (promoting coagulation), there is a potential for fetal harm. Females of reproductive potential should use effective contraception during treatment.

    Common adverse reactions (2% or greater): Injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.

    What This Means for Patients and Families

    For patients with hemophilia A or B who have inhibitors

    This is the population for whom this expansion matters most urgently. Inhibitor-positive patients, particularly those with hemophilia B inhibitors, have had no approved subcutaneous non-factor prophylactic therapy before this date. The BASIS inhibitor cohort’s 93% reduction in treated ABR compared to on-demand bypassing therapy represents a shift from a reactive management strategy to an active preventive one, with the bleed rate reduction that entails.

    If you or a family member has hemophilia with inhibitors and has been managed with on-demand bypassing agents, a conversation with your hematologist about whether Hympavzi is an appropriate prophylactic option is warranted.

    For families of children aged 6 to 11

    For young children with hemophilia, IV access for factor infusions has historically been the most practically difficult aspect of management, often requiring port placement and the risks that entails. A once-weekly subcutaneous injection administered by a caregiver at home, without routine blood draws for monitoring, represents a materially simpler treatment paradigm for this age group. The BASIS KIDS data showing a mean ABR of 1.3 in the 6-to-11 cohort supports the clinical adequacy of this approach.

    For children with hemophilia B specifically, this is the first approved subcutaneous non-factor prophylactic therapy in this age group, filling a gap that emicizumab’s mechanism could not address.

    For clinicians managing hemophilia

    The complete current Hympavzi indication covers hemophilia A and B, with or without inhibitors, in patients aged 6 years and older. This is a single once-weekly subcutaneous platform applicable across the majority of the hemophilia population. For patients who are appropriate candidates, the elimination of routine treatment-related laboratory monitoring removes a significant ongoing management burden.

    The thromboembolic warning and the D-dimer/prothrombin fragment 1.2 elevations associated with marstacimab require clinical awareness, particularly in patients who may develop thrombotic risk factors over time (surgery, immobilization, pregnancy). Risk-benefit discussions individualized to each patient’s circumstances remain the appropriate framework.

    For related HED coverage on other rare hematologic disease approvals in 2026, see our post on KRESLADI, the first gene therapy approved for severe leukocyte adhesion deficiency type I and our post on Decnupaz (pivekimab sunirine) approved for blastic plasmacytoid dendritic cell neoplasm.

    Sources

    Pfizer FDA approval press release: U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. Pfizer. June 8, 2026.

    Drugs.com approval news: U.S. FDA Approves Pfizer’s Hympavzi for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. drugs.com. June 8, 2026.

    BioPharm International clinical coverage: FDA Expands Pfizer’s Hympavzi Approval to Pediatric Hemophilia Patients and Those with Inhibitors. biopharminternational.com. June 2026.

    Hematology Advisor (BASIS inhibitor data): Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. hematologyadvisor.com. June 2026.

    Clinical Advisor detailed summary: Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. clinicaladvisor.com. June 2026.

    Conexiant clinical summary: FDA Expands Marstacimab Indication in Hemophilia A and B. conexiant.com. June 2026.

    CheckRare clinical coverage: FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia. checkrare.com. June 2026.

    BASIS trial registration: NCT03938792. ClinicalTrials.gov.

    BASIS KIDS trial registration: NCT05611801. ClinicalTrials.gov.

    Priority Review grant (sBLA): FDA Grants Priority Review for HYMPAVZI sBLA. Pfizer. 2026.

    Hympavzi original approval (October 2024): Hympavzi FDA Approval History. drugs.com.

    Hympavzi prescribing information: HYMPAVZI (marstacimab-hncq) Prescribing Information. Pfizer. 2026.

    TFPI biology and marstacimab mechanism: Tissue Factor Pathway Inhibitor. PMC6126283.

    Coagulation cascade: Coagulation Studies. StatPearls. NCBI.

    Hemophilia A overview: Hemophilia A. StatPearls. NCBI.

    Hemophilia B overview: Hemophilia B. StatPearls. NCBI.

    Hemophilia inhibitors: Factor VIII Inhibitors in Hemophilia A. PMC7155173.

    CDC hemophilia overview: Hemophilia. CDC.

    Patient resources: National Hemophilia Foundation | World Federation of Hemophilia | Pfizer Hympavzi patient support

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Hemophilia management is complex and requires individualized assessment by a hematologist experienced in bleeding disorders. Decisions about switching to or initiating Hympavzi should be made in consultation with a treating hematologist who can assess the patient’s inhibitor status, bleeding history, current prophylaxis regimen, and individual risk-benefit profile.
  • The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    I have all the data including the nuanced primary endpoint story. This is one of the more interesting approval stories of 2026 because the full ITT analysis technically missed the noninferiority margin but the FDA approved based on the modified ITT. That distinction must be presented honestly and clearly. Here is the full compliant post.

    The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    By M. Rodriguez, CST/CMA/CCA | Health Evidence Digest

    📌 The essentials On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder, MannKind Corporation) for use in children and adolescents aged 6 years and older with type 1 or type 2 diabetes. This expands Afrezza’s label beyond adults (approved June 2014) to include pediatric patients for the first time. Afrezza is the first and only inhaled mealtime insulin available to pediatric patients in the more than 100-year history of insulin therapy. The clinical basis: Phase 3 INHALE-1 trial (NCT04974528), 230 children and adolescents aged 4 to 17 years, 26-week randomized open-label comparison of Afrezza plus basal insulin versus multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin. Published in Diabetes Care, January 2026. Important nuance on the primary endpoint: the full intent-to-treat (ITT) analysis showed a between-group HbA1c difference of 0.435%, narrowly exceeding the prespecified noninferiority margin of 0.4%. This was attributed to a single non-adherent patient. A pre-specified modified ITT (mITT) analysis excluding this patient showed a difference of 0.370%, meeting noninferiority. The FDA approved based on the totality of evidence including the mITT analysis, long-term safety data, lung function data, and 20-plus years of Technosphere inhaled insulin research. Pulmonary safety: no significant difference in lung function between groups at 26 weeks. FEV1 remained within normal range throughout. No serious pulmonary adverse events. Secondary findings: significantly less weight gain and significantly higher treatment satisfaction in Afrezza-treated patients and parents versus MDI. Age minimum: 6 years and older. Price: eligible patients can access Afrezza for $35 or less per month through MannKind Cares.

    Insulin has been injected for more than 100 years. Every child diagnosed with type 1 diabetes has faced the same reality: multiple daily needle sticks, in school, at meals, at sports practice, at birthday parties, at sleepovers. For most of that century, there was no alternative.

    On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder) for use in children and adolescents aged 6 and older, making it the first needle-free mealtime insulin option ever available to pediatric patients. The drug that has been available to adult patients with diabetes since 2014 can now be prescribed to the children and adolescents for whom injection anxiety, school logistics, and social friction around insulin administration are documented barriers to adherence and glycemic control.

    The clinical evidence behind the approval requires honest presentation. The pivotal trial technically missed its pre-specified primary endpoint in the full analysis, approved based on a modified analysis and a totality of supporting evidence. That is a fact families and prescribers deserve to understand, not a reason to dismiss a drug that addresses one of the most durable unmet needs in pediatric diabetes care.

    Why Needle Anxiety in Children With Diabetes Is a Clinical Problem, Not a Parental Preference

    Needle anxiety in children with diabetes is one of the most consistently documented barriers to optimal insulin therapy in pediatric endocrinology. It is not simply a matter of children disliking injections; it is a behavioral pattern with measurable downstream consequences for glycemic control.

    Fear of injections drives dose skipping, delayed mealtime insulin administration, avoidance of insulin correction doses when blood glucose runs high, and in some cases refusal to initiate or intensify insulin therapy at diagnosis. In school settings specifically, the logistics of supervised insulin administration, the social visibility of the act, and the fear of peer reactions around needles create practical barriers that affect real-world glycemic management differently from how they appear in clinical trials conducted in controlled settings.

    The consequences of suboptimal mealtime insulin dosing in children compound over time. Chronic hyperglycemia accelerates the development of diabetic retinopathy, nephropathy, and neuropathy. In children who spend years with elevated post-meal glucose excursions because they skip or reduce mealtime insulin doses to avoid injections, the long-term risk burden is real and well-established.

    This is the clinical backdrop against which the Afrezza pediatric approval should be understood. Whether inhaled insulin achieves slightly different HbA1c values than injections in a controlled trial is relevant; whether it enables children who currently under-dose or skip mealtime insulin to take it more consistently is equally relevant, and arguably more important for the majority of real-world pediatric patients.

    What Afrezza Is and How the Technosphere Delivery System Works

    Afrezza is an inhaled formulation of recombinant human insulin that uses MannKind’s proprietary Technosphere drug delivery platform to achieve rapid pulmonary absorption. The drug is provided as a dry powder in a foil blister cartridge and is inhaled through a small, pocket-sized inhaler at the start of each meal.

    The Technosphere platform consists of fumaryl diketopiperazine (FDKP) particles, which are engineered to form microparticles that carry insulin into the deep lung. When these particles reach the alveolar surface, they dissolve rapidly in the aqueous lung lining, releasing insulin that is then absorbed into the pulmonary capillary bloodstream. This pulmonary absorption pathway bypasses the subcutaneous tissue depot that slows absorption with injected insulin.

    The pharmacokinetic result is what makes Afrezza clinically distinctive: it is the fastest-acting insulin available. In adults, Afrezza reaches peak insulin concentration within approximately 12 to 15 minutes of inhalation, compared to 55 to 90 minutes for rapid-acting injectable analogs like aspart, lispro, or glulisine. The duration of action is correspondingly shorter, approximately 3 hours, compared to 3 to 5 hours for injectable rapid-acting analogs.

    Why ultra-rapid onset matters for post-meal glucose control Mealtime insulin is meant to blunt the glucose spike that follows carbohydrate absorption. For injected rapid-acting insulin analogs, there is a well-documented mismatch: the insulin starts working 15 to 30 minutes after injection but glucose starts rising almost immediately upon eating. Patients are instructed to inject 15 to 20 minutes before eating, but adherence to pre-meal injection timing is low in practice, particularly in children and adolescents in real-world settings. Afrezza’s rapid onset means it can be inhaled at the start of the meal rather than before and still reach peak effect while glucose is rising from that meal. This timing advantage is pharmacologically meaningful and practically significant in school-age children who cannot predict meal timing, must eat quickly, or cannot leave class early to administer insulin before lunch.

    The INHALE-1 Trial: What the Data Shows, Including the Nuance

    Design

    INHALE-1 (NCT04974528) was a 26-week, open-label, randomized, multicenter Phase 3 clinical trial with a 26-week safety extension, enrolling children and adolescents aged 4 to 17 years with type 1 or type 2 diabetes. The open-label design was necessary because blinding inhaled versus injected insulin in children is not practically feasible.

    Enrollment (n=230): Randomized 1:1 to:

    • Afrezza inhalation powder plus basal insulin (n approximately 115)
    • Multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin (n approximately 115)

    Primary endpoint: Non-inferiority in change in HbA1c from baseline at 26 weeks, with a prespecified non-inferiority margin of 0.4%.

    Lung safety monitoring: FEV1 (forced expiratory volume in 1 second) and FVC measured at baseline, 12 weeks, and 26 weeks. Serious pulmonary adverse events tracked throughout.

    Key secondary endpoints: Weight change, treatment satisfaction (patients and parents), time in range (blood glucose 70 to 180 mg/dL), hypoglycemia frequency.

    The primary endpoint: what happened and why it matters

    This is the most clinically important and least straightforwardly reported aspect of the INHALE-1 data, and it deserves transparent presentation.

    HbA1c analysisBetween-group difference (Afrezza minus MDI)vs. 0.4% margin
    Full intent-to-treat (ITT) analysis (n=230)+0.435%Exceeds margin — non-inferiority NOT met
    Modified ITT (mITT) analysis (n=229, excluding 1 non-adherent patient)+0.370%Below margin — non-inferiority met

    Source: INHALE-1, NCT04974528. Published Diabetes Care. January 2026. Cardiology Advisor pre-approval coverage. April 2026.

    In the full ITT population, the mean HbA1c change was marginally worse in the Afrezza arm, with a between-group difference of 0.435%. This narrowly exceeded the prespecified non-inferiority margin of 0.4%, meaning the full analysis technically did not meet the primary endpoint as specified.

    According to MannKind and the investigating team, this outcome was driven by a single patient who did not adhere to the study protocol. Excluding this patient in the pre-specified mITT analysis produced a between-group difference of 0.370%, which falls within the 0.4% margin, meeting non-inferiority.

    The FDA approved Afrezza for pediatric use based on the totality of evidence, including the mITT analysis, 26-plus weeks of lung function data showing no meaningful pulmonary effects, 52-week safety extension data, and more than 20 years of Technosphere inhaled insulin research across thousands of patients including prior adult programs.

    It is worth being direct about what this means: the FDA reviewed the evidence and concluded the benefit-risk profile supports approval. The influence of a single non-adherent patient on the ITT analysis, the pre-specified nature of the mITT sensitivity analysis, and the favorable safety, satisfaction, and weight data collectively informed that conclusion. Patients and prescribers should be aware of this nuance; it does not invalidate the approval but it is relevant context for how to weigh the glycemic control evidence.

    Lung function: the key safety endpoint

    Lung function parameterAfrezza armMDI arm
    Mean FEV1 at baseline2.901 L (99.6% predicted)2.948 L (102.3% predicted)
    Mean FEV1 at week 262.934 L (96.6% predicted)2.957 L (98.0% predicted)
    Between-group difference in FEV1 changeNot statistically significantReference
    Serious pulmonary adverse eventsNone reportedNone reported
    Normal FEV1 range maintained throughoutYes, both groupsYes

    The lung function data is the most reassuring finding from INHALE-1 for families with legitimate concerns about what happens to a child’s lungs when they inhale insulin particles for months or years. In INHALE-1, both groups showed small declines in FEV1 percentage of predicted at 26 weeks, with no statistically significant difference between groups and both remaining solidly within normal range throughout.

    No serious pulmonary complications were reported in either group over 26 weeks or through the 52-week safety extension.

    Secondary endpoints: weight and satisfaction

    Secondary endpointFinding
    Weight gain at 26 weeksSignificantly less with Afrezza than MDI
    Treatment satisfaction (patient-reported)Significantly higher with Afrezza
    Parent treatment satisfactionSignificantly higher for parents of Afrezza-treated patients
    Hypoglycemia frequency at 26 weeksNo significant difference between groups

    The weight finding is clinically meaningful. Weight gain is a documented side effect of intensified insulin therapy in children and adolescents, and excess weight gain in a pediatric diabetes population has both metabolic and psychological implications. Less weight gain with equivalent glycemic control is a genuine secondary benefit.

    The treatment satisfaction finding matters for exactly the reason discussed above: a mealtime insulin option that children and parents prefer is more likely to be used consistently, particularly for the dose corrections and meal-related doses that are most commonly skipped.

    The Lung Cancer Warning: What It Means and Does Not Mean for Children

    Adults using Afrezza carry a warning about a potential lung cancer signal observed in adult clinical trials. This is a labeled warning that appears in the prescribing information and requires honest discussion.

    The signal emerged from long-term adult trials and post-market pharmacovigilance in adults with significant histories of smoking. A causal relationship between inhaled insulin use and lung cancer has not been established. The FDA’s assessment for the adult label concluded the benefit-risk profile remained favorable for indicated adult patients while warranting the warning and ongoing monitoring.

    For pediatric patients, several important contextual points apply:

    • The lung cancer signal, to the extent it exists, was observed in adults with long smoking histories
    • INHALE-1 enrolled children specifically excluding prior clinically significant pulmonary disease and requiring baseline normal lung function
    • No oncologic safety signals were observed in INHALE-1 or its extension
    • Afrezza is labeled for pediatric use starting at age 6, and the FDA reviewed pediatric-specific lung function data before granting the approval

    The warning is present in the pediatric label. Parents and prescribers should be aware of it, discuss it in the context of the full benefit-risk picture for an individual child, and continue routine follow-up monitoring of pulmonary function as clinically indicated.

    Safety: The Full Prescribing Information Picture

    Boxed warning (applies to adult label; relevant context for pediatric prescribers):

    • Acute bronchospasm in patients with chronic lung disease (asthma, COPD)
    • Contraindicated in patients with chronic lung disease
    • Lung cancer signal in adults (see above)

    Contraindications:

    • Patients with chronic lung disease including asthma and COPD (increased risk of acute bronchospasm)
    • During episodes of hypoglycemia
    • Hypersensitivity to any component of the formulation

    Warnings and precautions:

    • Acute bronchospasm: patients should have a short-acting bronchodilator available; spirometry is recommended before initiating treatment in patients with mild or moderate lung disease
    • Hypoglycemia: as with all insulins, the risk of hypoglycemia requires monitoring
    • Hypokalemia: insulin drives potassium into cells; monitor in patients at risk
    • Fluid retention and heart failure (applies to combination with thiazolidinediones, not standard pediatric use)

    Lung function monitoring: Perform FEV1 assessment before initiating Afrezza, every 6 months during treatment, and as clinically indicated.

    Who Should and Should Not Use Afrezza

    Appropriate candidates for Afrezza in the pediatric setting

    • Children and adolescents aged 6 and older with type 1 or type 2 diabetes who require mealtime insulin
    • Patients with significant needle anxiety affecting mealtime insulin adherence
    • Patients who frequently skip or reduce mealtime doses due to injection reluctance
    • Patients and families who prefer the flexibility and convenience of inhaled administration for school, social, and athletic contexts
    • Patients with normal baseline lung function per spirometry

    Contraindicated or not appropriate

    • Any patient with asthma, COPD, or other chronic pulmonary disease (absolute contraindication)
    • Patients with FEV1 below 70% predicted (exclude from eligibility per trial criteria)
    • Patients with recent respiratory tract infections (hold until resolved)
    • Patients under 6 years of age
    • Afrezza is not a replacement for basal insulin and cannot be used as a basal insulin; it is a mealtime (prandial) insulin only

    Practical note for younger patients (ages 6 to 7)

    Afrezza administration requires the ability to use the inhaler device correctly and to exhale fully before inhalation. Children aged 6 to 7 may require more practice and caregiver supervision to ensure consistent technique. Pediatric endocrinologists and diabetes educators should assess inhaler technique specifically in younger patients before transitioning to Afrezza independently.

    Dosing

    Afrezza doses are based on the patient’s usual rapid-acting insulin analog dose, converted according to the prescribing information dose conversion table. The drug is available in single-use cartridges of 4 units, 8 units, and 12 units of inhaled insulin. Key dose conversion guidance (from the January 2026 label update providing starting dose guidance for patients switching from insulin pumps or MDI) is available in the full prescribing information.

    Timing: inhale at the beginning of each meal. Do not use during or after a meal. Do not use for correction doses if the patient is already hypoglycemic.

    Access and Cost

    MannKind has announced that eligible patients can access Afrezza for $35 or less per month through its MannKind Cares patient support program. For a condition requiring daily medication for life, this cost point is a meaningful access consideration and compares favorably with list pricing for injectable rapid-acting insulin analogs prior to the insulin price cap legislation and assistance programs currently in effect.

    For related HED coverage on insulin access and recent approvals, see our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, our post on Langlara and what interchangeable insulin biosimilars mean for affordability, and our post on Linzess expanding to children as young as 2 as another pediatric label expansion approval from the same week.

    Sources

    FDA approval announcement and MannKind press release: MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes. GlobeNewswire. May 29, 2026.

    Drugs.com approval news: MannKind Announces FDA Approval of Afrezza for Children and Adolescents Aged 6 and Older. drugs.com. May 29, 2026.

    AJMC clinical summary: FDA Approves Inhaled Insulin for Children, Adolescents With Diabetes. ajmc.com. May 2026.

    Pharmacy Times approval coverage: FDA Approves Afrezza Insulin Inhalation Powder for Children, Adolescents With Type 1 and Type 2 Diabetes. pharmacytimes.com. May 2026.

    HCPLive approval coverage: FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes. hcplive.com. May 2026.

    Patient Care Online: FDA Approves First Inhaled Mealtime Insulin for Children and Adolescents With Diabetes. patientcareonline.com. May 2026.

    TechTimes decision day coverage (with primary endpoint nuance): Inhaled Insulin for Children: FDA Reaches Decision Deadline for Afrezza. techtimes.com. May 29, 2026.

    INHALE-1 primary publication: INHALE-1 Phase 3 results. Diabetes Care. January 2026.

    INHALE-1 ADA 2025 presentation: Phase 3 INHALE-1 results presented at 85th ADA Scientific Sessions. Chicago, June 2025.

    INHALE-1 trial registration: NCT04974528. ClinicalTrials.gov.

    sBLA acceptance (October 2025): MannKind Announces US FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years. GlobeNewswire. October 13, 2025.

    Cardiology Advisor pre-approval detailed data summary: FDA Drug Approval Decisions Expected in May 2026. thecardiologyadvisor.com. April 2026.

    Afrezza original adult FDA approval (June 2014): FDA approves Afrezza to treat diabetes. FDA.gov. June 2014.

    Afrezza prescribing information: Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind. 2026.

    Needle anxiety and pediatric diabetes: Fear of Needles and Its Impact on Diabetes Management. PMC8261965.

    Diabetic complications prevention: Preventing Diabetes Problems. NIDDK.

    Patient resources: JDRF (type 1 diabetes) | American Diabetes Association: Mealtime Insulin | MannKind Cares patient support | Afrezza patient website

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Afrezza is contraindicated in patients with chronic lung disease including asthma and COPD. All decisions about mealtime insulin therapy for children and adolescents with diabetes should be made in close consultation with a pediatric endocrinologist or diabetes care team familiar with the child’s complete health history, current diabetes management, and pulmonary function status.

  • The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    📌 The essentials On May 8, 2026, the FDA approved Ocrevus (ocrelizumab, Genentech) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10 years and older who weigh at least 25 kg (approximately 55 pounds). This is Ocrevus’s first pediatric indication, expanding its label beyond adults. Ocrevus becomes only the second FDA-approved disease-modifying therapy for pediatric RRMS, after fingolimod (Gilenya, Novartis), and the first approved high-efficacy anti-CD20 therapy for this population. The clinical basis: Phase 3 OPERETTA 2 trial (NCT05123703), 187 pediatric patients aged 10 to 17 years with RRMS, randomized double-blind comparison of ocrelizumab versus fingolimod. Primary endpoint: ocrelizumab was non-inferior to fingolimod in reducing annualized relapse rate. MRI superiority: 48% reduction in new or enlarging T2 lesions (p=0.001) and 87% reduction in gadolinium-enhancing T1 lesions (p=0.001) versus fingolimod. Safety: no adverse events led to treatment withdrawal in the ocrelizumab arm. How it is given: 600 mg intravenous infusion every 24 weeks (same dose and schedule as adults). Weight minimum: the drug is not known to be safe or effective in children under 10 years of age or weighing less than 25 kg.

    Multiple sclerosis in children and adolescents is a different clinical scenario than most people picture when they think of MS. Pediatric-onset MS (POMS) represents approximately 3 to 5% of all MS cases globally, with an estimated 5,000 to 10,000 children and adolescents affected in the United States. The condition is not mild: children with POMS typically have higher relapse rates than adults, more rapid accumulation of new brain lesions on MRI, and a relapsing disease course in the vast majority of cases. What they have historically had is very few approved treatment options.

    Until May 8, 2026, fingolimod (Gilenya) was the only FDA-approved disease-modifying therapy for pediatric RRMS, a status it has held since its pediatric approval in 2018. Every other MS treatment used in children and adolescents was prescribed off-label, without the clinical trial evidence base that formal approval requires.

    That changed when the FDA approved Ocrevus (ocrelizumab) for RRMS in patients aged 10 and older, based on the Phase 3 OPERETTA 2 trial. For the first time, a high-efficacy anti-CD20 B-cell depleting therapy is formally available for pediatric patients who have not responded adequately to first-line agents or whose disease activity warrants a more aggressive approach from the start.

    What Pediatric-Onset Multiple Sclerosis Is and Why Treatment Is Urgent

    Pediatric-onset MS is defined as MS with symptom onset before age 18. Children and adolescents with POMS experience the same types of episodes as adults, including optic neuritis, limb weakness, sensory disturbance, brainstem and cerebellar dysfunction, and cognitive slowing. But several features distinguish POMS from typical adult-onset disease.

    Higher initial disease activity: Children with POMS typically have higher relapse rates than adult patients early in the disease course. Brain MRI at diagnosis often shows extensive T2 lesion burden. The inflammatory activity is often vigorous, reflecting the heightened immune responsiveness of the developing immune system.

    Predominantly relapsing course: Nearly all pediatric MS cases are relapsing-remitting, not progressive, at onset. This is both a prognostic advantage (the disease course is more amenable to disease modification) and a treatment priority (relapses in developing brains carry distinct risks for cognitive and neurological development that are not fully quantified in adults).

    Cognitive burden: Cognitive impairment is documented in a substantial proportion of children with MS, affecting processing speed, attention, memory, and executive function. Because POMS occurs during a critical period of brain development and education, the impact of unchecked disease activity on long-term cognitive trajectory is a distinct and serious concern.

    Long disease duration ahead: A child diagnosed at age 12 faces potentially decades of living with MS before the disease is biologically comparable to someone diagnosed at 50. The cumulative burden of every avoided relapse, every suppressed lesion, and every year of preserved neurological function compounds over that longer horizon.

    Why fingolimod was the only approved option for so long, and what its limitations are Fingolimod (Gilenya) was the first FDA-approved MS therapy for pediatric patients, receiving its pediatric RRMS approval in May 2018 based on the Phase 3 PARADIGMS trial. It works by sequestering lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing inflammation. It is effective and its oral administration is an advantage for younger patients. But it carries significant safety concerns: a first-dose cardiac monitoring requirement (due to the risk of bradycardia and heart block), risk of serious infections including PML and cryptococcal meningitis, varicella zoster reactivation, and ophthalmologic monitoring requirements for macular edema. In a pediatric population, these monitoring requirements represent a real burden on families, schools, and clinical teams. Until OPERETTA 2, the absence of a high-efficacy alternative with a clinically distinct mechanism and monitoring profile left neurologists and families with limited flexibility.

    How Ocrelizumab Works and Why B-Cell Depletion Matters in MS

    Ocrelizumab is a humanized anti-CD20 monoclonal antibody. CD20 is a surface protein expressed on B cells throughout most of their development, from pre-B cells through mature B cells, but not on plasma cells or hematopoietic stem cells. When ocrelizumab binds CD20, it triggers B-cell depletion through three mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction.

    The role of B cells in MS pathogenesis has been substantially clarified in the decade since ocrelizumab’s original approval. B cells contribute to MS inflammation not just as antibody-producing cells but as antigen-presenting cells that activate CD4+ and CD8+ T cells, as producers of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and as modulators of the inflammatory microenvironment within CNS lesions. Depleting B cells interrupts these multiple contributions to disease activity, producing the robust efficacy on both relapse rates and MRI lesion accumulation that has made ocrelizumab one of the most effective MS therapies in adult practice.

    In the pediatric setting, ocrelizumab’s mechanism offers specific theoretical advantages: because POMS is characterized by highly active inflammatory disease, the near-complete B-cell depletion produced by ocrelizumab (blood B-cell counts typically fall to undetectable levels within 2 weeks of the first infusion and remain suppressed for the 24-week dosing interval) may be particularly well-matched to the disease biology. The OPERETTA 2 data tests this hypothesis directly.

    The OPERETTA 2 Trial: Full Results

    Design

    OPERETTA 2 (NCT05123703) was a randomized, double-blind, double-dummy, multicenter Phase 3 noninferiority trial. The double-dummy design means that all patients received both an IV infusion and an oral daily capsule, with one being the active drug and the other a matching placebo, ensuring neither patients nor investigators knew which treatment was assigned.

    The trial enrolled 187 pediatric patients aged 10 to 17 years with RRMS, randomized 1:1 to:

    • Ocrelizumab 600 mg intravenous infusion every 24 weeks, plus oral placebo daily (n approximately 94)
    • Fingolimod 0.5 mg oral capsule daily, plus intravenous placebo infusion every 24 weeks (n approximately 93)

    OPERETTA 2 was designed to demonstrate non-inferiority of ocrelizumab to fingolimod. The dose of ocrelizumab (600 mg every 24 weeks) is the same as the approved adult dose, a decision supported by pharmacokinetic and pharmacodynamic data from the companion OPERETTA 1 study that characterized ocrelizumab’s PK profile in the pediatric age range and confirmed that the adult dose produces comparable drug exposure in children aged 10 and older weighing at least 25 kg.

    Primary endpoint

    OutcomeOcrelizumabFingolimodComparison
    Annualized relapse rate (ARR)Significantly reducedReferenceNon-inferior (rate ratio 0.52; 95% CI 0.19 to 1.33)
    Primary non-inferiority endpointMetReferencep-value consistent with non-inferiority

    MRI endpoints (superiority)

    MRI OutcomeOcrelizumabFingolimodComparison
    New or enlarging T2 hyperintense lesions per MRI scan3.7787.235Relative reduction 47.8%; p=0.001
    Mean T1 gadolinium-enhancing lesions at week 120.0310.243Relative reduction 87.2%; p=0.001

    Source: OPERETTA 2 trial, NCT05123703. Genentech/FDA press release, May 8, 2026. Presented at AAN 2026 and published in advance of peer-reviewed journal publication.

    Interpreting the results

    The primary non-inferiority finding means ocrelizumab reduced annualized relapse rates in a manner that was statistically no worse than fingolimod, the current standard of care for this population. The 95% confidence interval for the rate ratio (0.19 to 1.33) is wide, reflecting the challenge of powering pediatric trials with small populations, but the point estimate (0.52) suggests that relapses were approximately 48% less frequent with ocrelizumab, a numerically superior result that did not reach formal superiority on the relapse endpoint.

    The MRI superiority findings are the more clinically discriminating results. A 48% reduction in new or enlarging T2 lesions and an 87% reduction in gadolinium-enhancing lesions versus fingolimod at week 12 are substantial advantages on the imaging markers that most directly reflect ongoing inflammatory disease activity. These MRI findings align with what was observed in adult comparisons of ocrelizumab versus other MS therapies: the anti-CD20 mechanism produces particularly deep suppression of new lesion formation, which correlates with long-term disability protection in adult studies.

    Safety in OPERETTA 2

    The safety profile of ocrelizumab in pediatric patients in OPERETTA 2 was consistent with its well-established nine-year adult safety record. The most commonly reported adverse events were infusion reactions, infections, and decreases in immunoglobulin levels, identical in type to what is documented in adult trials.

    Notably, no adverse events led to treatment withdrawal in the ocrelizumab arm during the double-blind period. This finding on discontinuation due to adverse events is clinically meaningful given that tolerability-driven discontinuation is one of the practical challenges of fingolimod’s first-dose cardiac monitoring requirement and ongoing ophthalmologic surveillance.

    MSBase Registry real-world data presented at the 2026 CMSC Annual Meeting further supports the OPERETTA 2 findings: an analysis of pediatric-onset MS patients in the registry showed that ocrelizumab maintained similar effectiveness and safety in pediatric-onset disease compared to young-adult onset disease, providing external validation from clinical practice in countries where ocrelizumab has been used off-label or under compassionate access in pediatric patients.

    Ocrevus’s Full Approved Indication Picture After May 2026

    With the pediatric RRMS approval, Ocrevus now carries the following FDA-approved indications:

    IndicationPopulationApproval date
    Relapsing forms of MS (CIS, RRMS, active SPMS)AdultsMarch 2017
    Primary progressive MSAdultsMarch 2017
    RRMSPediatric patients aged 10 years and older weighing at least 25 kgMay 8, 2026

    Ocrevus also has a subcutaneous formulation, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), approved in September 2024 for adults, which delivers the same dose subcutaneously in 10 minutes rather than the 3.5-hour intravenous infusion. The subcutaneous formulation is currently approved for adults only; the pediatric indication uses the intravenous formulation.

    Safety Considerations for the Pediatric Population

    The safety profile of ocrelizumab is well-established from more than nine years of adult use and now confirmed in OPERETTA 2 for the pediatric setting. Key considerations for parents and pediatric neurologists:

    Infusion reactions: The most common adverse event during ocrelizumab treatment is infusion-related reactions occurring during or within 24 hours of infusion. Pre-medication with corticosteroids, antihistamines, and analgesics is administered before each infusion per protocol. These reactions are typically mild to moderate and manageable.

    Infections: Because B-cell depletion reduces one component of humoral immunity, patients on ocrelizumab are at modestly increased risk of respiratory infections, particularly upper respiratory tract infections. Serious infections occurred at low rates in both adult and pediatric trials. Opportunistic infections including PML (caused by JC virus) have been reported rarely in adult patients, primarily in those with additional immunocompromising factors.

    Decreasing immunoglobulins: Long-term B-cell depletion leads to gradual decline in IgG and IgM levels over years of treatment. Monitor immunoglobulin levels periodically. Significant hypogammaglobulinemia may require dose adjustment or management in some patients.

    Vaccinations: Live vaccines should not be administered during treatment or until B cells have reconstituted after stopping treatment. All recommended immunizations should be completed before initiating Ocrevus. This is particularly important in the pediatric setting where routine childhood vaccination schedules need to be coordinated with treatment initiation.

    PML risk: Ocrevus carries a boxed warning for progressive multifocal leukoencephalopathy (PML), though the absolute risk appears substantially lower than with natalizumab (Tysabri). No cases of PML were reported in OPERETTA 2.

    Dosing and Administration for Pediatric Patients

    ParameterDetails
    Approved dose (ages 10 and older, weight at least 25 kg)600 mg IV every 24 weeks
    First doseTwo 300 mg infusions given 2 weeks apart
    Subsequent dosesSingle 600 mg infusion every 24 weeks
    Pre-medication requiredMethylprednisolone (or equivalent corticosteroid) IV, antihistamine, and optional antipyretic before each infusion
    Infusion duration (600 mg)Approximately 3.5 hours
    SettingHealthcare facility with emergency equipment and resuscitation capability available
    Weight requirementAt least 25 kg (approximately 55 lbs)
    Age lower limit10 years and older
    Not forChildren under 10 years of age or weighing less than 25 kg

    What This Approval Means for Families and Pediatric Neurologists

    For families of children with RRMS

    For the first time, a family whose child has RRMS has a choice between two FDA-approved treatment options rather than only one. Ocrevus, administered every six months as an intravenous infusion, offers a different monitoring profile, mechanism of action, and efficacy signal than daily oral fingolimod.

    Practical considerations for families when discussing this option with your child’s neurologist:

    • Ocrevus is infused twice a year. Fingolimod is taken daily. For some families, twice-yearly clinic visits for infusion are more manageable than ensuring daily adherence; for others, the infusion schedule is a barrier.
    • The first-dose cardiac monitoring requirement with fingolimod is not required with Ocrevus.
    • The ophthalmologic monitoring required with fingolimod is not required with Ocrevus.
    • The 87% reduction in gadolinium-enhancing lesions at week 12 versus fingolimod in OPERETTA 2 indicates a measurably deeper suppression of active inflammation with Ocrevus in the pediatric trial.
    • All immunizations should be current and any live vaccines completed before starting Ocrevus. This timing requires planning with your child’s pediatrician and neurologist.

    For pediatric neurologists

    OPERETTA 2 provides the first randomized head-to-head controlled evidence comparing a high-efficacy anti-CD20 therapy to fingolimod in pediatric RRMS. The non-inferiority on ARR combined with superiority on both MRI endpoints justifies positioning ocrelizumab as a strong option for treatment-naive patients with active disease, not just as a step-up therapy after fingolimod failure.

    The absence of treatment withdrawal due to adverse events in the ocrelizumab arm is a meaningful tolerability signal in a population where treatment persistence over years and decades is the goal. Monitoring requirements for ocrelizumab are primarily infusion reaction surveillance, immunoglobulin levels, and standard infection monitoring, rather than the cardiac and ophthalmologic monitoring that fingolimod requires.

    The American Academy of Neurology and the International Pediatric MS Study Group will be updating their guidance frameworks in response to this approval. The National MS Society’s healthcare providers section provides updated clinical resources.

    For families: the National MS Society and Can Do MS both maintain dedicated pediatric MS resources. The International Pediatric MS Study Group connects families with specialized clinical expertise.

    For related HED coverage of other neurological condition approvals and anti-CD20 therapy advances in 2026, see our post on Fasenra (benralizumab) approved for hypereosinophilic syndrome as another example of a biologic agent expanding from adult to pediatric and rare disease settings, and our post on VYVGART and the first approval covering all forms of myasthenia gravis.

    Sources

    FDA approval announcement: FDA approves ocrelizumab for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. FDA.gov. May 8, 2026.

    Genentech press release: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis in Pediatric Patients 10 Years of Age and Older. gene.com. May 8, 2026.

    Drugs.com approval news: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age and Older. drugs.com. May 2026.

    NeurologyLive clinical summary: FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. neurologylive.com. May 2026.

    Neurology Advisor detailed coverage: Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis. neurologyadvisor.com. May 2026.

    Pharmacy Times clinical review: FDA Approves Ocrelizumab for Pediatric Relapsing-Remitting Multiple Sclerosis. pharmacytimes.com. May 2026.

    Medscape coverage: FDA Approves Ocrelizumab for Pediatric Relapsing MS. medscape.com. May 2026.

    MS News Today coverage: In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS. multiplesclerosisnewstoday.com. May 2026.

    CMSC 2026 real-world data: CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. neurologylive.com. May 2026.

    Practical Neurology: FDA Approves Ocrevus for Pediatric Relapsing-Remitting MS. practicalneurology.com. May 2026.

    OPERETTA 2 trial registration: NCT05123703. ClinicalTrials.gov.

    Ocrevus original FDA approval: FDA approves ocrelizumab for multiple sclerosis. FDA.gov. March 2017.

    Fingolimod pediatric approval: FDA approves fingolimod for pediatric patients with multiple sclerosis. FDA.gov. 2018.

    Ocrevus prescribing information: OCREVUS (ocrelizumab) Prescribing Information. Genentech. 2026.

    Ocrelizumab mechanism review: CD20-directed B-cell depleting therapies in MS. PMC6369883.

    Pediatric MS StatPearls: Pediatric Multiple Sclerosis. StatPearls. NCBI.

    Pediatric MS cognitive effects: Cognitive Impairment in Pediatric Multiple Sclerosis. PMC7897219.

    ADCC mechanism: Antibody-Dependent Cell-Mediated Cytotoxicity. StatPearls. NCBI.

    National MS Society pediatric resources: Pediatric MS. nationalmssociety.org.

    Patient resources: National MS Society: Pediatric MS | International Pediatric MS Study Group | Can Do MS | American Academy of Neurology

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about MS treatment, including the choice of disease-modifying therapy for pediatric patients, should be made in close consultation with a pediatric neurologist or MS specialist experienced in pediatric-onset multiple sclerosis.
  • Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    📌 The essentials On May 21, 2026, the FDA approved Linzess (linaclotide 72 mcg, Ironwood Pharmaceuticals/AbbVie) for functional constipation in pediatric patients aged 2 years and older. This expands Linzess’s prior pediatric FC approval (ages 6 and older, approved 2023) to now include children ages 2 to 5 years. Linzess remains the only FDA-approved prescription therapy for pediatric functional constipation. Clinical basis: a Phase 3 randomized, placebo-controlled, double-blind 12-week trial in patients aged 2 to 5 years with functional constipation, showing that linaclotide 72 mcg significantly increased spontaneous bowel movements versus placebo with a consistent safety profile. This approval was supported by efficacy data from the earlier Phase 3 trial in children aged 6 to 17 years published in The Lancet Gastroenterology and Hepatology. Complete Linzess pediatric FC indication: ages 2 to 17 years, 72 mcg once daily. Critical safety warning: Linzess is contraindicated in patients under 2 years of age due to the risk of serious dehydration based on neonatal animal data. This age floor is absolute. The most common adverse event in pediatric patients is diarrhea. Severe diarrhea requires discontinuation and rehydration. Linzess is not a laxative and should not be used in patients with known or suspected mechanical gastrointestinal obstruction.

    Functional constipation in children is one of the most common complaints seen in pediatric primary care and pediatric gastroenterology. It accounts for approximately 25% of all pediatric gastroenterology visits and up to 5% of all general pediatric office visits in the United States. For a condition that affects millions of children, the treatment options have been remarkably limited: behavioral and dietary interventions, over-the-counter osmotic laxatives like polyethylene glycol (MiraLAX), and in more refractory cases, office-based and specialist-managed regimens that still often fall short.

    Until 2023, there was no FDA-approved prescription drug specifically for functional constipation in children. That changed when linaclotide was approved for children aged 6 to 17 years. On May 21, 2026, the FDA extended that approval to children as young as 2, supported by a Phase 3 trial specifically designed and conducted in the 2-to-5 age group.

    This post covers what functional constipation is in children, how linaclotide works, what the evidence shows for the 2-to-5 age group, how to administer the drug in young children, and what the critical safety considerations are for parents and clinicians.

    What Functional Constipation Is and Why Young Children Are Particularly Affected

    Functional constipation is a clinical diagnosis based on symptoms rather than a structural or metabolic cause. In the pediatric population, it is defined using Rome IV criteria as the presence of at least two of the following symptoms over at least one month, without evidence of organic pathology:

    • Fewer than 3 spontaneous defecations per week
    • History of excessive stool retention or fecal withholding
    • History of painful or hard bowel movements
    • History of large-diameter stools that may obstruct the toilet
    • Presence of a large fecal mass in the rectum on examination

    The estimated worldwide prevalence in preschool-aged children is approximately 3%, though regional variation is substantial and the true prevalence may be higher given that many cases are managed at home without clinical contact. In the United States, functional constipation affects an estimated 1 in 20 young children at any given time.

    Why the 2-to-5 age group is particularly vulnerable

    Preschool-aged children are at elevated risk for functional constipation for several physiological and behavioral reasons. Toilet training is a common precipitant: the transition from diapers to toilet use can trigger withholding behaviors, particularly if a child associates the toilet with discomfort or anxiety. Any painful stool passage creates a cycle: pain leads to withholding, withholding leads to harder and larger stools, larger stools cause more pain on passage, which reinforces withholding further.

    Dietary transitions in this age group, including the shift to family foods, weaning from breast milk, and inconsistent fiber intake, also contribute. Limited communication ability in younger children means parents often underestimate the degree of discomfort or may not recognize withholding behaviors for what they are.

    Untreated functional constipation in young children has real consequences beyond discomfort. Chronic fecal retention can lead to fecal impaction, which may require emergency intervention. Encopresis (overflow fecal incontinence) can develop and carries significant social and psychological consequences for school-aged children. The earlier effective treatment is initiated, the lower the risk of this cascade.

    What the Rome IV criteria mean in practice for ages 2 to 5 For the youngest patients covered by the expanded Linzess indication, the Rome IV criteria for toddlers and preschoolers specifically recognize behaviors that are not always recognized as constipation by parents. Fecal withholding, in which a child deliberately tightens pelvic floor muscles and assumes characteristic postures to prevent defecation, is one of the most common presentations. Parents often mistake withholding postures for straining. The assessment of whether stools are hard, the frequency of natural bowel movements, and the presence of pain should all be evaluated in context of the child’s developmental stage, dietary history, and any identifiable precipitants. Organic causes of constipation in this age group that must be excluded before a functional diagnosis is made include Hirschsprung’s disease (rare but important), hypothyroidism, celiac disease, and anatomical abnormalities. A thorough evaluation by the pediatrician or pediatric gastroenterologist before initiating prescription therapy is appropriate.

    How Linzess Works: The GC-C Mechanism

    Linaclotide is a guanylate cyclase-C (GC-C) agonist. It is a 14-amino-acid peptide structurally similar to endogenous GC-C-activating peptides (guanylin and uroguanylin) that are produced naturally by intestinal epithelial cells.

    When linaclotide binds to GC-C receptors on the luminal surface of intestinal epithelial cells, it activates a signaling cascade that produces cyclic GMP (cGMP) inside those cells. Elevated intracellular cGMP activates a chloride and bicarbonate channel (CFTR) in the intestinal epithelium, which secretes fluid into the intestinal lumen. The resulting increase in luminal fluid content softens stool and accelerates intestinal transit.

    Locally elevated cGMP also activates pathways that reduce the activity of pain-sensing nerve fibers in the intestinal wall. This visceral analgesic effect is believed to contribute to reduced abdominal discomfort and pain associated with constipation, though the clinical relevance of this mechanism in pediatric patients has not been specifically established.

    Critically, linaclotide acts almost entirely in the gut. Systemic absorption is minimal: the drug is not measurably detected in the bloodstream at therapeutic doses. This limited absorption is one reason the pediatric side effect profile is favorable compared to systemically acting drugs.

    The Pediatric Evidence Base: What the Trials Showed

    Linzess’s expanded approval for ages 2 to 5 years builds on a pediatric evidence program that has been developed over several years.

    Phase 3 trial in children aged 6 to 17 (the foundational pediatric trial)

    The original pediatric FC indication (ages 6 to 17) was supported by data from Trial 7 (NCT04026113), a 12-week, double-blind, placebo-controlled, randomized, multicenter Phase 3 trial in 328 children aged 6 to 17 years meeting modified Rome III criteria for functional constipation, published in The Lancet Gastroenterology and Hepatology.

    Key results from Trial 7:

    OutcomeLinaclotide 72 mcgPlacebo
    Spontaneous bowel movement frequency rateSignificantly higherReference
    Patients with at least 1 SBM within 24 hours of first dose30.5%20.7% (p=0.043)
    Patients with at least 1 SBM within 48 hours of first dose56.7%38.4% (p=0.0009)
    Most common adverse event (diarrhea)4% (7 of 164)Lower rate
    Safety vs. adultsConsistent profile—

    Source: Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Phase 3 trial in children aged 2 to 5 (the basis for the May 2026 expansion)

    The May 2026 approval for ages 2 to 5 was based on a Phase 3, 12-week, randomized, placebo-controlled trial specifically designed for this younger age group. This trial evaluated linaclotide 72 mcg in children aged 2 to 5 years with functional constipation, demonstrating that the drug significantly increased spontaneous bowel movements versus placebo with a consistent safety profile in this age range.

    The trial specifically confirmed that the mechanism is active in this age group: GC-C intestinal expression in children aged 2 to less than 18 years was examined in a clinical study and showed no age-dependent trend, providing the biological rationale for why the same dose produces consistent effects across the 2-to-17 age range. Below age 2, insufficient data on GC-C expression precludes safe use, which is the basis for the absolute age-2 lower limit.

    Both the pediatric 6-to-17 trial and the new 2-to-5 trial data are also supported by efficacy extrapolation from robust adult trials in chronic idiopathic constipation, providing multiple layers of evidence that the mechanism operates consistently.

    The Full Linzess Pediatric Approval Picture: A Rapidly Expanding Label

    The May 2026 approval is the most recent in a series of pediatric Linzess approvals that have expanded its use substantially since the original 2012 adult approval:

    IndicationPopulationApproval date
    Chronic idiopathic constipation (CIC)AdultsAugust 2012
    Irritable bowel syndrome with constipation (IBS-C)AdultsAugust 2012
    Functional constipation (FC)Pediatric patients aged 6 to 17 yearsSeptember 2023
    IBS-CPediatric patients aged 7 years and olderNovember 2025
    Functional constipation (FC) expandedPediatric patients aged 2 years and olderMay 21, 2026

    Linzess is now the only FDA-approved prescription drug for functional constipation in children from age 2 through age 17. It is also the first and only FDA-approved prescription therapy for IBS-C in children aged 7 and older.

    Dosing and Administration

    Recommended dose for all pediatric FC patients (ages 2 to 17): Linaclotide 72 mcg orally once daily.

    Timing: On an empty stomach, at least 30 minutes before the first meal of the day.

    Administration in young children (ages 2 to 5): Young children cannot swallow capsules whole. The capsule contents can be administered in two ways, as outlined in the prescribing information:

    • With applesauce: Open the capsule, sprinkle the contents onto one teaspoon of room-temperature applesauce, and have the child swallow the mixture immediately without chewing. Do not store the mixture.
    • With water: Open the capsule, pour the contents into a clean cup containing approximately 1 teaspoon (about 5 mL) of room-temperature water, gently swirl for approximately 20 seconds, and have the child swallow the mixture immediately. Do not store the mixture.

    Do not administer by crushing or dissolving the capsule itself. Do not add the contents to infant formula, breast milk, or beverages other than water.

    If a dose is missed: Take it as soon as possible on the same day. If that day has passed, skip the missed dose and resume the next day. Do not double up.

    Duration of therapy: The appropriate treatment duration should be determined by the prescribing clinician based on treatment response and the child’s clinical course. Functional constipation in young children can be a chronic, relapsing condition, and ongoing therapy may be appropriate in some children after other management strategies have been optimized.

    Safety: What Parents and Clinicians Need to Know

    Contraindication in patients under 2 years of age

    Linzess is absolutely contraindicated in patients younger than 2 years. In neonatal mouse studies, linaclotide caused increased fluid secretion through age-dependent elevated GC-C activity, which led to rapid and fatal dehydration. The 2-year minimum age reflects the human biological evidence that GC-C receptor expression does not show the same age-dependent elevation pattern in children 2 years and older, but insufficient data exists for those under 2 to confirm equivalent safety.

    This is not a soft guideline. It is an absolute contraindication with an FDA boxed-equivalent warning.

    Diarrhea: the most important adverse event to monitor

    Diarrhea is the most commonly reported adverse reaction in both adult and pediatric clinical trials. In the pediatric 6-to-17 trial (Trial 7), diarrhea occurred in 4% of linaclotide-treated patients compared with lower rates in the placebo arm. In younger children, dehydration risk from diarrhea is proportionally higher than in older patients because of lower total body water reserves.

    What to do if diarrhea occurs:

    • Mild diarrhea: monitor hydration closely; ensure the child is drinking fluids
    • Severe diarrhea: discontinue Linzess immediately and ensure adequate rehydration; contact the prescribing clinician

    Parents should be counseled specifically about diarrhea recognition and the dehydration signs in young children before starting therapy: decreased urine output, dry mucous membranes, reduced tears, and decreased activity level are clinical indicators of dehydration requiring medical evaluation.

    Mechanical obstruction: do not use in obstruction

    Linzess is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. All patients should be evaluated for structural causes of constipation before initiating therapy.

    Systemic absorption: minimal

    Because linaclotide is minimally absorbed into the bloodstream, it does not produce systemic drug effects at therapeutic doses. The safety profile reflects predominantly local GI effects rather than systemic medication reactions.

    What This Means for Parents Navigating Functional Constipation in a Young Child

    When to consider discussing Linzess with your pediatrician

    Linzess is a prescription medication intended for children with functional constipation who have not responded adequately to dietary and behavioral interventions and to over-the-counter laxative therapy (such as polyethylene glycol). It is not a first-line treatment for all constipation in young children, and most children will begin with simpler, less intensive approaches.

    A conversation about Linzess is appropriate when:

    • Your child ages 2 to 5 has been diagnosed with functional constipation by a pediatrician or pediatric gastroenterologist
    • You have tried dietary modification (increased fluid and fiber intake), toilet training adjustments, and at least one course of over-the-counter osmotic laxative therapy
    • Constipation continues to affect your child’s quality of life, comfort, or daily functioning despite these approaches
    • Your pediatrician has excluded organic causes of constipation appropriate to your child’s age

    How to administer to a toddler or preschooler

    The applesauce administration method is typically easiest for most children ages 2 to 5. The granules from the capsule are nearly tasteless, and mixing them into a small amount of applesauce is usually well-accepted. If your child does not tolerate applesauce, the water slurry method is available. Consistency in daily timing (before breakfast each morning) helps establish the routine.

    What to watch for during the first weeks of therapy

    In the first 1 to 4 weeks, parents should monitor for:

    • Improvement in bowel movement frequency and stool consistency (the expected benefit)
    • Diarrhea or loose stools (the most common side effect; mild cases may not require stopping the drug)
    • Signs of dehydration if diarrhea occurs (reduced wet diapers or urination, dry mouth, no tears when crying, unusual lethargy)
    • Worsening of abdominal discomfort or new symptoms that were not present before starting

    Keep your pediatrician informed of the response within the first 4 weeks. If your child has not shown improvement in spontaneous bowel movement frequency and stool consistency after a reasonable trial period, discuss with your provider whether continuing therapy is appropriate.

    For related HED coverage of gastrointestinal health and gut-targeted drug approvals, see our post on Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis, which covers another gut-targeted therapy approval, and our post on the Fasenra approval for hypereosinophilic syndrome as an example of how rare condition approvals are expanding across pediatric populations in 2026.

    Sources

    FDA approval announcement: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC). FDA.gov. May 21, 2026.

    Ironwood Pharmaceuticals press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. investor.ironwoodpharma.com. May 27, 2026.

    BioSpace press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. biospace.com. May 2026.

    Drugs.com approval news: FDA Approves Linzess (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. drugs.com. May 2026.

    HCPLive clinical coverage: FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years and Older. hcplive.com. May 2026.

    Conexiant/Pediatrics clinical news: FDA OKs Linaclotide in Young Children. conexiant.com. May 2026.

    Phase 3 Trial 7 primary publication (Lancet GH): Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Trial 7 registration: NCT04026113. ClinicalTrials.gov.

    FDA first pediatric FC approval press release (September 2023): FDA Approves First Treatment for Pediatric Functional Constipation. FDA.gov. September 2023.

    FDA pediatric IBS-C approval (November 2025): FDA Approves First Drug for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation. FDA.gov. November 2025.

    Linzess prescribing information: LINZESS (linaclotide) Prescribing Information. Ironwood Pharmaceuticals/AbbVie. Updated 2026.

    Functional constipation in children (NIDDK): Constipation in Children. niddk.nih.gov.

    Functional constipation StatPearls: Functional Constipation. StatPearls. NCBI.

    Linaclotide mechanism: Linaclotide. StatPearls. NCBI.

    GC-C receptor biology: Guanylate Cyclase-C in GI Tract. PMC4415491.

    Patient resources: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) | NIDDK Constipation in Children | Linzess patient resources

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Linzess (linaclotide) is a prescription medication. Decisions about treatment for pediatric functional constipation, including the appropriateness of prescription therapy, should be made in consultation with a qualified pediatrician or pediatric gastroenterologist. Do not administer Linzess to children under 2 years of age.